Keros Therapeutics (KROS) Financials

$14.57 +0.41 (+2.90%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$14.38 -0.20 (-1.34%)

As of 05/23/2025 06:23 PM Eastern

Annual Income Statements for Keros Therapeutics

This table shows Keros Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-187	-153	-105
Consolidated Net Income / (Loss)	-187	-153	-105
Net Income / (Loss) Continuing Operations	-187	-153	-105
Total Pre-Tax Income	-187	-153	-105
Total Operating Income	-211	-170	-115
Total Gross Profit	3.55	0.15	0.00
Total Revenue	3.55	0.15	0.00
Operating Revenue	3.55	0.15	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	214	170	115
Selling, General & Admin Expense	41	35	28
Research & Development Expense	174	135	87
Total Other Income / (Expense), net	24	17	10
Interest Expense	0.00	0.00	0.00
Interest & Investment Income	25	15	11
Other Income / (Expense), net	-0.95	2.19	-0.61
Income Tax Expense	0.30	0.00	0.00
Basic Earnings per Share	($5.00)	($5.20)	($4.15)
Weighted Average Basic Shares Outstanding	37.44M	29.45M	25.24M
Diluted Earnings per Share	($5.00)	($5.20)	($4.15)
Weighted Average Diluted Shares Outstanding	37.44M	29.45M	25.24M
Weighted Average Basic & Diluted Shares Outstanding	40.56M	35.98M	28.54M

This table shows Keros Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-46	-53	-45	-43	-40	-39	-38	-36	-30	-24
Consolidated Net Income / (Loss)	-46	-53	-45	-43	-40	-39	-38	-36	-30	-24
Net Income / (Loss) Continuing Operations	-46	-53	-45	-43	-40	-39	-38	-36	-30	-24
Total Pre-Tax Income	-46	-53	-45	-43	-40	-39	-38	-36	-30	-24
Total Operating Income	-53	-59	-50	-48	-46	-43	-41	-39	-32	-28
Total Gross Profit	3.04	0.39	0.04	0.08	0.14	0.01	0.00	0.00	-	0.00
Total Revenue	3.04	0.39	0.04	0.08	0.14	0.01	0.00	0.00	-	0.00
Operating Revenue	3.04	0.39	0.04	0.08	0.14	0.01	0.00	0.00	-	0.00
Total Operating Expenses	56	59	50	49	47	43	41	39	32	28
Selling, General & Admin Expense	11	9.82	9.96	10	9.11	9.15	8.80	7.78	7.09	6.94
Research & Development Expense	46	49	41	38	37	34	33	31	25	21
Total Other Income / (Expense), net	7.53	5.70	5.18	5.37	6.21	3.84	3.83	3.07	2.18	4.47
Interest & Investment Income	7.76	5.79	5.38	5.81	3.76	3.91	3.99	3.11	-	3.71
Other Income / (Expense), net	-0.23	-0.09	-0.20	-0.44	2.46	-0.07	-0.16	-0.04	-	0.76
Basic Earnings per Share	($1.13)	($1.41)	($1.25)	($1.21)	($1.34)	($1.33)	($1.27)	($1.26)	($1.09)	($0.92)
Weighted Average Basic Shares Outstanding	37.44M	37.59M	36.10M	35.69M	29.45M	29.67M	29.60M	28.37M	25.24M	25.55M
Diluted Earnings per Share	($1.13)	($1.41)	($1.25)	($1.21)	($1.34)	($1.33)	($1.27)	($1.26)	($1.09)	($0.92)
Weighted Average Diluted Shares Outstanding	37.44M	37.59M	36.10M	35.69M	29.45M	29.67M	29.60M	28.37M	25.24M	25.55M
Weighted Average Basic & Diluted Shares Outstanding	40.56M	40.51M	37.52M	36.08M	35.98M	29.96M	29.66M	29.58M	28.54M	-

This table details how cash moves in and out of Keros Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	229	52	49
Net Cash From Operating Activities	-161	-125	-70
Net Cash From Continuing Operating Activities	-160	-125	-70
Net Income / (Loss) Continuing Operations	-187	-153	-105
Consolidated Net Income / (Loss)	-187	-153	-105
Depreciation Expense	1.23	0.82	0.67
Amortization Expense	1.82	1.55	-
Non-Cash Adjustments To Reconcile Net Income	35	29	16
Changes in Operating Assets and Liabilities, net	-10	-3.03	18
Net Cash From Investing Activities	-1.93	-2.46	-1.24
Net Cash From Continuing Investing Activities	-1.93	-2.46	-1.24
Purchase of Property, Plant & Equipment	-1.93	-2.46	-1.24
Net Cash From Financing Activities	392	179	120
Net Cash From Continuing Financing Activities	392	179	120
Repurchase of Common Equity	-0.17	-0.09	-0.09
Issuance of Common Equity	380	176	120
Other Financing Activities, net	12	3.23	0.82

This table details how cash moves in and out of Keros Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	29	125	-37	111	43	-34	-29	72	40	24
Net Cash From Operating Activities	-46	-31	-40	-45	-25	-34	-31	-34	-21	-25
Net Cash From Continuing Operating Activities	-46	-30	-39	-44	-26	-34	-31	-34	-21	-25
Net Income / (Loss) Continuing Operations	-46	-53	-45	-43	-40	-39	-38	-36	-30	-24
Consolidated Net Income / (Loss)	-46	-53	-45	-43	-40	-39	-38	-36	-30	-24
Depreciation Expense	0.33	0.31	0.31	0.28	0.25	0.21	0.19	0.17	0.13	0.13
Amortization Expense	0.57	0.56	0.35	0.34	0.34	0.34	0.35	0.52	-	-
Non-Cash Adjustments To Reconcile Net Income	9.20	8.82	8.79	8.07	7.32	8.71	7.04	5.69	1.36	4.98
Changes in Operating Assets and Liabilities, net	-9.66	13	-3.66	-9.89	6.75	-4.17	-0.89	-4.73	6.79	-6.20
Net Cash From Investing Activities	-0.29	-0.39	-0.31	-0.95	-0.54	-0.55	-0.31	-1.06	-0.35	-0.18
Net Cash From Continuing Investing Activities	-0.29	-0.39	-0.31	-0.95	-0.54	-0.55	-0.31	-1.06	-0.35	-0.18
Purchase of Property, Plant & Equipment	-0.29	-0.39	-0.31	-0.95	-0.54	-0.55	-0.31	-1.06	-0.35	-0.18
Net Cash From Financing Activities	76	156	3.53	157	69	0.28	1.74	108	61	49
Net Cash From Continuing Financing Activities	76	156	3.56	157	69	0.28	1.74	108	61	49
Issuance of Common Equity	73	155	0.63	151	69	-	-	107	61	48
Other Financing Activities, net	2.45	1.01	2.97	5.72	0.80	0.31	1.74	0.37	0.10	0.10

This table presents Keros Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	616	370	307
Total Current Assets	589	347	286
Cash & Equivalents	560	331	279
Accounts Receivable	2.74	0.14	0.00
Prepaid Expenses	26	16	6.72
Plant, Property, & Equipment, net	4.24	4.13	2.02
Total Noncurrent Assets	23	19	19
Other Noncurrent Operating Assets	23	19	19
Total Liabilities & Shareholders' Equity	616	370	307
Total Liabilities	44	38	29
Total Current Liabilities	27	24	17
Accounts Payable	4.60	5.45	3.34
Accrued Expenses	21	18	13
Other Current Liabilities	1.98	1.01	0.46
Total Noncurrent Liabilities	17	13	13
Other Noncurrent Operating Liabilities	17	13	13
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	572	332	277
Total Preferred & Common Equity	572	332	277
Preferred Stock	0.00	0.00	0.00
Total Common Equity	572	332	277
Common Stock	1,140	714	506
Retained Earnings	-569	-381	-228

This table presents Keros Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023
Total Assets	579	455	486	326	356	384
Total Current Assets	552	433	463	304	334	362
Cash & Equivalents	531	406	442	288	322	351
Accounts Receivable	0.39	0.00	0.23	-	-	-
Prepaid Expenses	21	27	20	17	12	11
Plant, Property, & Equipment, net	4.37	4.29	4.43	3.36	3.09	2.93
Total Noncurrent Assets	23	18	18	18	19	19
Other Noncurrent Operating Assets	23	18	18	18	19	19
Total Liabilities & Shareholders' Equity	579	455	486	326	356	384
Total Liabilities	46	34	32	30	30	29
Total Current Liabilities	29	21	19	17	16	15
Accounts Payable	4.98	6.54	4.99	3.87	4.15	4.68
Accrued Expenses	22	14	13	12	12	11
Other Current Liabilities	1.86	1.10	1.05	0.61	0.00	0.00
Total Noncurrent Liabilities	17	13	13	14	14	14
Other Noncurrent Operating Liabilities	17	13	13	14	14	14
Total Equity & Noncontrolling Interests	533	421	454	296	326	355
Total Preferred & Common Equity	533	421	454	296	326	355
Preferred Stock	0.00	0.00	0.00	-	-	-
Total Common Equity	533	421	454	296	326	355
Common Stock	1,056	891	878	637	628	619
Retained Earnings	-523	-470	-425	-341	-302	-264

This table displays calculated financial ratios and metrics derived from Keros Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	2,250.99%	0.00%	-100.00%
EBITDA Growth	-26.22%	-44.15%	-105.39%
EBIT Growth	-26.25%	-45.36%	-103.33%
NOPAT Growth	-24.06%	-48.05%	-103.63%
Net Income Growth	-22.46%	-46.15%	-78.20%
EPS Growth	3.85%	-25.30%	-64.68%
Operating Cash Flow Growth	-29.20%	-77.71%	-12.73%
Free Cash Flow Firm Growth	-30.00%	-85.45%	-15.59%
Invested Capital Growth	990.24%	165.60%	-112.37%
Revenue Q/Q Growth	445.31%	1,787.50%	0.00%
EBITDA Q/Q Growth	-4.59%	-6.87%	0.00%
EBIT Q/Q Growth	-4.69%	-7.91%	0.00%
NOPAT Q/Q Growth	-3.33%	-9.32%	0.00%
Net Income Q/Q Growth	-3.19%	-7.39%	0.00%
EPS Q/Q Growth	4.03%	-5.05%	0.00%
Operating Cash Flow Q/Q Growth	-14.64%	-3.33%	0.00%
Free Cash Flow Firm Q/Q Growth	-15.41%	-4.19%	-2,184.78%
Invested Capital Q/Q Growth	440.31%	-86.59%	0.00%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	0.00%
EBITDA Margin	-5,879.94%	-109,523.18%	0.00%
Operating Margin	-5,938.96%	-112,543.71%	0.00%
EBIT Margin	-5,965.83%	-111,090.73%	0.00%
Profit (Net Income) Margin	-5,277.55%	-101,319.21%	0.00%
Tax Burden Percent	100.16%	100.00%	100.00%
Interest Burden Percent	88.32%	91.20%	90.71%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-2,326.34%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-2,317.42%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	2,284.88%	0.00%	0.00%
Return on Equity (ROE)	-41.46%	-50.19%	-40.22%
Cash Return on Invested Capital (CROIC)	-2,492.73%	-11,411.79%	0.00%
Operating Return on Assets (OROA)	-42.96%	-49.57%	0.00%
Return on Assets (ROA)	-38.01%	-45.21%	0.00%
Return on Common Equity (ROCE)	-41.46%	-50.19%	-40.22%
Return on Equity Simple (ROE_SIMPLE)	-32.78%	-46.05%	-37.73%
Net Operating Profit after Tax (NOPAT)	-148	-119	-80
NOPAT Margin	-4,157.27%	-78,780.60%	0.00%
Net Nonoperating Expense Percent (NNEP)	-8.93%	-11.15%	-9.56%
Return On Investment Capital (ROIC_SIMPLE)	-25.82%	-35.81%	-28.96%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	1,148.00%	23,068.87%	0.00%
R&D to Revenue	4,890.96%	89,574.83%	0.00%
Operating Expenses to Revenue	6,038.96%	112,643.71%	0.00%
Earnings before Interest and Taxes (EBIT)	-212	-168	-115
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-209	-165	-115
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.12	3.59	4.46
Price to Tangible Book Value (P/TBV)	1.12	3.59	4.46
Price to Revenue (P/Rev)	180.63	7,888.64	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	7.00	806.79	0.00
Enterprise Value to Revenue (EV/Rev)	22.90	5,695.62	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.99	-1.00	-0.98
Leverage Ratio	1.09	1.11	1.08
Compound Leverage Factor	0.96	1.01	0.98
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	7.35	17.01	24.05
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	21.45	14.25	17.27
Quick Ratio	20.50	13.59	16.86
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-158	-122	-66
Operating Cash Flow to CapEx	-8,330.86%	-5,053.08%	-5,645.61%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-65,596.00
Operating Cash Flow to Interest Expense	0.00	0.00	-70,062.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-71,303.00
Efficiency Ratios	-	-	-
Asset Turnover	0.01	0.00	0.00
Accounts Receivable Turnover	2.46	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.85	0.05	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	148.31	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	148.31	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	12	1.07	-1.63
Invested Capital Turnover	0.56	-0.54	0.00
Increase / (Decrease) in Invested Capital	11	2.69	-15
Enterprise Value (EV)	81	860	958
Market Capitalization	641	1,191	1,237
Book Value per Share	$14.11	$11.09	$10.99
Tangible Book Value per Share	$14.11	$11.09	$10.99
Total Capital	572	332	277
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-560	-331	-279
Capital Expenditures (CapEx)	1.93	2.46	1.24
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.51	-8.23	-9.83
Debt-free Net Working Capital (DFNWC)	561	323	269
Net Working Capital (NWC)	561	323	269
Net Nonoperating Expense (NNE)	40	34	24
Net Nonoperating Obligations (NNO)	-560	-331	-279
Total Depreciation and Amortization (D&A)	3.05	2.37	0.67
Debt-free, Cash-free Net Working Capital to Revenue	42.59%	-5,448.34%	0.00%
Debt-free Net Working Capital to Revenue	15,815.30%	213,854.30%	0.00%
Net Working Capital to Revenue	15,815.30%	213,854.30%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($5.00)	($5.20)	($4.15)
Adjusted Weighted Average Basic Shares Outstanding	37.44M	29.45M	25.24M
Adjusted Diluted Earnings per Share	($5.00)	($5.20)	($4.15)
Adjusted Weighted Average Diluted Shares Outstanding	37.44M	29.45M	25.24M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	40.56M	35.98M	28.54M
Normalized Net Operating Profit after Tax (NOPAT)	-148	-119	-80
Normalized NOPAT Margin	-4,157.27%	-78,780.60%	0.00%
Pre Tax Income Margin	-5,269.10%	-101,319.21%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	-115,403.00
NOPAT to Interest Expense	0.00	0.00	-80,353.00
EBIT Less CapEx to Interest Expense	0.00	0.00	-116,644.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	-81,594.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.09%	-0.06%	-0.08%

This table displays calculated financial ratios and metrics derived from Keros Therapeutics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	2,027.27%	4,750.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-21.10%	-35.23%	-22.07%	-26.38%	-36.39%	-57.99%	-34.99%	-59.16%	0.00%	-33.89%
EBIT Growth	-21.56%	-35.53%	-22.04%	-25.73%	-37.67%	-59.28%	-35.41%	-61.27%	0.00%	-33.84%
NOPAT Growth	-14.64%	-35.53%	-22.02%	-24.73%	-45.35%	-54.70%	-34.53%	-61.11%	0.00%	-38.52%
Net Income Growth	-14.37%	-34.27%	-20.67%	-20.42%	-35.42%	-67.77%	-37.55%	-48.04%	0.00%	0.00%
EPS Growth	15.67%	-6.02%	1.57%	3.97%	-22.94%	-44.57%	-12.39%	-24.75%	0.00%	0.00%
Operating Cash Flow Growth	-80.71%	10.25%	-29.09%	-30.16%	-18.73%	-38.13%	-36.49%	-2,299.09%	0.00%	-70.36%
Free Cash Flow Firm Growth	-35.85%	7.80%	-18.55%	-36.16%	-362.37%	-70.32%	-125.87%	-31.99%	55.95%	-56.82%
Invested Capital Growth	990.24%	-72.94%	255.53%	223.60%	165.60%	0.00%	173.76%	0.00%	-112.37%	100.00%
Revenue Q/Q Growth	684.02%	948.65%	-55.42%	-41.96%	1,687.50%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	9.15%	-15.78%	-3.48%	-2.07%	-1.45%	-4.52%	-7.14%	-20.06%	-17.52%	10.70%
EBIT Q/Q Growth	8.96%	-16.02%	-3.51%	-2.12%	-1.50%	-4.47%	-6.64%	-21.74%	-17.44%	11.19%
NOPAT Q/Q Growth	9.21%	-16.29%	-4.03%	-4.37%	-7.34%	-4.70%	-6.35%	-21.62%	-14.24%	8.96%
Net Income Q/Q Growth	13.09%	-17.01%	-4.97%	-7.13%	-2.04%	-5.16%	-4.75%	-20.48%	-26.41%	13.78%
EPS Q/Q Growth	19.86%	-12.80%	-3.31%	9.70%	-0.75%	-4.72%	-0.79%	-15.60%	-18.48%	18.58%
Operating Cash Flow Q/Q Growth	-50.85%	23.37%	10.68%	-75.03%	25.08%	-10.22%	9.94%	-59.66%	12.84%	-8.91%
Free Cash Flow Firm Q/Q Growth	-35.65%	23.55%	-10.12%	-18.97%	7.94%	1.71%	-26.48%	-303.98%	66.09%	-30.35%
Invested Capital Q/Q Growth	440.31%	-85.71%	30.85%	979.17%	-86.59%	87.74%	19.10%	318.77%	0.00%	100.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-1,728.44%	-14,915.46%	-135,089.19%	-58,197.59%	-30,361.54%	-534,950.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-1,750.62%	-15,117.78%	-136,321.62%	-58,413.25%	-32,486.01%	-541,000.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-1,758.15%	-15,141.49%	-136,851.35%	-58,939.76%	-30,768.53%	-541,837.50%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-1,513.02%	-13,648.45%	-122,316.22%	-51,944.58%	-28,141.96%	-493,000.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.66%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	99.80%	100.00%
Interest Burden Percent	85.50%	90.14%	89.38%	88.13%	91.46%	90.99%	90.39%	92.02%	93.17%	86.39%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-685.73%	-1,364.19%	-2,681.62%	-1,270.75%	0.00%	-762.26%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-683.77%	-1,361.29%	-2,678.89%	-1,268.44%	0.00%	-755.91%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	674.17%	1,344.69%	2,609.74%	1,244.82%	0.00%	735.60%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-11.56%	-19.50%	-71.88%	-25.92%	-50.19%	-26.66%	-47.09%	-32.76%	-40.22%	0.00%
Cash Return on Invested Capital (CROIC)	-2,492.73%	-2,713.38%	-1,481.61%	-1,774.85%	-11,411.79%	-2,937.76%	-2,552.51%	-5,301.16%	0.00%	0.00%
Operating Return on Assets (OROA)	-12.66%	-21.77%	-91.42%	-31.70%	-13.73%	-26.57%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-10.90%	-19.62%	-81.71%	-27.93%	-12.56%	-24.18%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-11.56%	-19.50%	-71.88%	-25.92%	-50.19%	-26.66%	-47.09%	-32.76%	-40.22%	0.00%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-34.08%	-39.93%	-35.31%	0.00%	-48.16%	-38.78%	-32.76%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-37	-41	-35	-34	-33	-30	-29	-27	-22	-20
NOPAT Margin	-1,225.44%	-10,582.45%	-95,425.14%	-40,889.28%	-22,740.21%	-378,700.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-1.96%	-2.91%	-2.73%	-2.31%	-2.53%	-6.35%	-3.18%	-4.89%	-2.89%	-3.55%
Return On Investment Capital (ROIC_SIMPLE)	-6.52%	-	-	-	-9.79%	-	-	-	-8.06%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	350.59%	2,530.93%	26,921.62%	12,419.28%	6,367.13%	114,350.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	1,500.03%	12,686.86%	109,500.00%	46,093.98%	26,218.88%	426,750.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	1,850.62%	15,217.78%	136,421.62%	58,513.25%	32,586.01%	541,100.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-53	-59	-51	-49	-44	-43	-41	-39	-32	-27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-53	-58	-50	-48	-43	-43	-41	-38	-32	-27
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.12	4.09	3.92	5.25	3.59	3.20	3.64	3.43	4.46	0.00
Price to Tangible Book Value (P/TBV)	1.12	4.09	3.92	5.25	3.59	3.20	3.64	3.43	4.46	0.00
Price to Revenue (P/Rev)	180.63	3,347.02	6,084.99	10,179.70	7,888.64	118,207.82	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	7.00	766.26	82.59	168.60	806.79	82.75	204.69	243.89	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	22.90	2,531.83	4,587.35	8,288.92	5,695.62	82,221.20	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.99	-0.99	-0.97	-0.98	-1.00	-0.97	-1.00	-0.99	-0.98	-1.01
Leverage Ratio	1.09	1.09	1.09	1.08	1.11	1.10	1.08	1.08	1.08	1.05
Compound Leverage Factor	0.93	0.99	0.97	0.95	1.02	1.00	0.98	1.00	1.01	0.91
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	8.20	27.64	28.28	44.39	18.11	17.82	23.24	24.61	24.94	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	21.45	19.03	20.37	24.74	14.25	18.23	20.77	23.43	17.27	0.00
Quick Ratio	20.50	18.31	19.10	23.65	13.59	17.24	20.01	22.73	16.86	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-48	-35	-46	-42	-35	-38	-39	-31	-7.62	-22
Operating Cash Flow to CapEx	-15,919.72%	-7,901.55%	-12,839.03%	-4,710.36%	-4,705.92%	-6,178.55%	-9,913.83%	-3,223.63%	-6,109.12%	-13,978.41%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	2.46	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.85	0.17	0.07	0.06	0.05	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	148.31	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	148.31	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	12	2.15	15	12	1.07	7.95	4.23	3.56	-1.63	0.00
Invested Capital Turnover	0.56	0.13	0.03	0.03	-0.54	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	11	-5.80	11	7.95	2.69	7.95	9.97	3.56	-15	2.87
Enterprise Value (EV)	81	1,648	1,243	1,940	860	658	867	867	958	969
Market Capitalization	641	2,179	1,649	2,382	1,191	946	1,189	1,218	1,237	969
Book Value per Share	$14.11	$14.20	$11.66	$12.62	$11.09	$9.97	$11.03	$12.44	$10.99	$0.00
Tangible Book Value per Share	$14.11	$14.20	$11.66	$12.62	$11.09	$9.97	$11.03	$12.44	$10.99	$0.00
Total Capital	572	533	421	454	332	296	326	355	277	0.00
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-560	-531	-406	-442	-331	-288	-322	-351	-279	0.00
Capital Expenditures (CapEx)	0.29	0.39	0.31	0.95	0.54	0.55	0.31	1.06	0.35	0.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.51	-7.65	5.61	1.97	-8.23	-0.16	-3.81	-4.67	-9.83	0.00
Debt-free Net Working Capital (DFNWC)	561	523	411	444	323	288	318	347	269	0.00
Net Working Capital (NWC)	561	523	411	444	323	288	318	347	269	0.00
Net Nonoperating Expense (NNE)	8.75	12	9.95	9.18	7.72	9.14	8.57	8.60	7.35	3.93
Net Nonoperating Obligations (NNO)	-560	-531	-406	-442	-331	-288	-322	-351	-279	0.00
Total Depreciation and Amortization (D&A)	0.90	0.88	0.65	0.62	0.58	0.55	0.55	0.69	0.13	0.13
Debt-free, Cash-free Net Working Capital to Revenue	42.59%	-1,174.35%	2,068.63%	839.74%	-5,448.34%	-1,987.50%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	15,815.30%	80,343.93%	151,833.58%	189,917.95%	213,854.30%	3,596,675.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	15,815.30%	80,343.93%	151,833.58%	189,917.95%	213,854.30%	3,596,675.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.13)	($1.41)	($1.25)	($1.21)	($1.34)	($1.33)	($1.27)	($1.26)	($1.09)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	37.44M	37.59M	36.10M	35.69M	29.45M	29.67M	29.60M	28.37M	25.24M	0.00
Adjusted Diluted Earnings per Share	($1.13)	($1.41)	($1.25)	($1.21)	($1.34)	($1.33)	($1.27)	($1.26)	($1.09)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	37.44M	37.59M	36.10M	35.69M	29.45M	29.67M	29.60M	28.37M	25.24M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	40.56M	40.51M	37.52M	36.08M	35.98M	29.96M	29.66M	29.58M	28.54M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-37	-41	-35	-34	-33	-30	-29	-27	-22	-20
Normalized NOPAT Margin	-1,225.44%	-10,582.45%	-95,425.14%	-40,889.28%	-22,740.21%	-378,700.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-1,503.16%	-13,648.45%	-122,316.22%	-51,944.58%	-28,141.96%	-493,000.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.09%	0.00%	0.00%	0.00%	-0.06%	0.00%	0.00%	0.00%	-0.08%	0.00%

Frequently Asked Questions About Keros Therapeutics' Financials

When does Keros Therapeutics's financial year end?

According to the most recent income statement we have on file, Keros Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Keros Therapeutics' net income changed over the last 2 years?

Keros Therapeutics' net income appears to be on an upward trend, with a most recent value of -$187.35 million in 2024, rising from -$104.68 million in 2022. The previous period was -$152.99 million in 2023. Check out Keros Therapeutics' forecast to explore projected trends and price targets.

What is Keros Therapeutics's operating income?

Keros Therapeutics's total operating income in 2024 was -$210.83 million, based on the following breakdown:

Total Gross Profit: $3.55 million
Total Operating Expenses: $214.38 million

How has Keros Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Keros Therapeutics' total revenue changed from $0.00 in 2022 to $3.55 million in 2024, a change of 355,000,000.0%.

How much debt does Keros Therapeutics have?

Keros Therapeutics' total liabilities were at $44.33 million at the end of 2024, a 17.2% increase from 2023, and a 51.0% increase since 2022.

How much cash does Keros Therapeutics have?

In the past 2 years, Keros Therapeutics' cash and equivalents has ranged from $279.05 million in 2022 to $559.93 million in 2024, and is currently $559.93 million as of their latest financial filing in 2024.

How has Keros Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Keros Therapeutics' book value per share changed from 10.99 in 2022 to 14.11 in 2024, a change of 28.4%.

Related Companies

This page (NASDAQ:KROS) was last updated on 5/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Keros Therapeutics (KROS) Financials

Frequently Asked Questions About Keros Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Keros Therapeutics (KROS) Financials

Annual Income Statements for Keros Therapeutics

Quarterly Income Statements for Keros Therapeutics

Annual Cash Flow Statements for Keros Therapeutics

Quarterly Cash Flow Statements for Keros Therapeutics

Annual Balance Sheets for Keros Therapeutics

Quarterly Balance Sheets for Keros Therapeutics

Annual Metrics And Ratios for Keros Therapeutics

Quarterly Metrics And Ratios for Keros Therapeutics

Frequently Asked Questions About Keros Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools